Develops targeted therapies for patients with genetically-defined cancers, focusing on mTOR pathway inhibitors.
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing precision therapies for genetically defined cancers characterized by alterations in mTOR pathway genes. Founded in 2007 and based in Pacific Palisades, California, Aadi focuses on developing and bringing to market innovative treatments that target specific genomic profiles associated with mTOR pathway activation. Their primary drug candidate, FYARRO, utilizes a formulation of sirolimus bound to albumin, currently undergoing evaluation across various cancer types with known mTOR pathway abnormalities.
FYARRO, Aadi Bioscience's lead therapeutic candidate, represents a novel approach in oncology by leveraging the synergistic potential of sirolimus and albumin in its formulation. The drug is being studied not only in tumor types traditionally associated with mTOR pathway activation but also in tumor-agnostic indications, aiming to address specific genetic alterations linked to mTOR pathway dysregulation. This strategic focus underscores Aadi's commitment to personalized medicine and its pursuit of therapies tailored to the molecular characteristics of individual patients.
With a robust pipeline and a foundation built on extensive research and development expertise, Aadi Bioscience continues to push the boundaries of canccer treatment innovation. By harnessing the therapeutic potential of mTOR pathway modulation, the company aims to deliver meaningful clinical benefits to patients while advancing the understanding and management of genetically defined cancers.